

**ASX Announcement | 26 October 2023  
Vioneering Technologies (ASX:VTI)**

**Adjournment of Special Meeting of Stockholders**

**Vioneering Technologies, Inc. (ASX: VTI)** ('Vioneering', 'VTI' or 'the **Company**'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, advises that its special meeting of stockholders, which was scheduled to be held today, 26 October 2023 at 8.00 a.m. Australian Eastern Daylight Time (on Wednesday, 25 October 2023 at 5.00 p.m. U.S. Eastern Daylight Time) (**Special Meeting**), was convened and adjourned without any business being conducted, due to the lack of the required quorum.

The required quorum for convening the Annual Meeting is a simple majority (i.e. more than 50%) of the Company's outstanding common stock (calculated as of the record date of 9 October 2023) being present at the Special Meeting. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 8% of the shares of the Company's common stock outstanding and entitled to vote at the Special Meeting (including shares of common stock underlying CHESS Depositary Interests (**CDIs**)).

As a result of the lack of a required quorum, the Special Meeting has been adjourned to 8.00 a.m. on Thursday, 2 November 2023 Australian Eastern Daylight Time (5.00 p.m. on Wednesday, 1 November 2023 U.S. Eastern Daylight Time) (**Adjourned Special Meeting**) to allow additional time for the Company's stockholders and holders of the Company's CDIs to vote on the proposals set forth in the Company's Notice of Special Meeting of Stockholders (**Notice**) filed with the Australian Securities Exchange (**ASX**) on 12 October 2023, and thereby satisfy the required quorum for the meeting.

Shareholders as of 9 October 2023 (**Record Date**) may vote before the Adjourned Special Meeting at [www.investorvote.com.au/VTI-SM](http://www.investorvote.com.au/VTI-SM) by no later than 6.00 a.m. on Thursday, 2 November 2023 Australian Eastern Daylight Time (3.00 p.m. on Wednesday, 1 November 2023 U.S. Eastern Daylight Time). CDI holders at the Record Date may vote before the Adjourned Special Meeting at [www.investorvote.com.au/vti](http://www.investorvote.com.au/vti) by no later than 8.00 a.m. Australian Eastern Daylight Time on Tuesday, 31 October 2023 (5.00 p.m. U.S. Eastern Daylight Time on Monday, 30 October 2023).

The Adjourned Special Meeting will be conducted virtually via a live webcast. The same virtual meeting link provided in the Notice <http://meetnow.global/MPLW9QW> should be used to access the Adjourned Special Meeting. During the current adjournment period, the Company will continue to solicit votes from its stockholders and CDI holders with respect to the proposals set forth in the Company's Notice.

**Ends.**

**This release was authorized by the CEO, Dr. Juan Carlos Aragón.**

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO & CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

### **About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day™ Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtivision.com](http://www.vtivision.com) or call +1 844-884-5367, ext. 104.

### **Foreign ownership restrictions**

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans, and expectations and information currently available to management.

All statements that address operating performance, events, or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the ongoing impact of COVID-19 on the trading conditions impacting VTI, the financial markets, and the health services worldwide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments, or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX88